ClinicalTrials.gg
CompletedNCT00406835Updated Dec 4, 2006

Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases

An observational study in Brain Metastasis, sponsored by Hokkaido University Hospital. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-12-04.

Sponsored by Hokkaido University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Defined population
Time perspective
Prospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Brain Neoplasms with a site in Japan — 2 open to participants now, 8 under way, 3 of them phase 3. Brain Neoplasms · Japan.

Started
1999
the only one that year
Observational
Only one
of the 21
Registered
3rd of 21
by date
Lead sponsor
1 of 21
Hokkaido University Hospital

Among the 21 studies in Brain Neoplasms with a site in Japan, this one is the only one that started in 1999, is the only observational one, and was the 3rd registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

2 of the 21 studies in Brain Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Brain Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to determine if WBRT combined with SRS resulted in improvements in survival, brain tumor control, functional preservation rate, and frequency of neurologic death.

Read the detailed description

Whole-Brain Radiation Therapy (WBRT) had been a mainstay in the treatment of brain metastases. However, treatment strategy which rely on Stereotactic Radiosurgery (SRS) has becoming popular in Japan. It is not well understood if the Whole-Brain Radiation Therapy (WBRT) combined with Stereotactic Radiosurgery (SRS) resulted in improvements in survival, brain tumor control, functional preservation rate, and frequency of neurologic death. In orer to determine the role of WBRT, we conducted prospective randomized trial between WBRT+SRS and SRS-alone for 1-4 brain metastatic patients.

03

Conditions studied

  • Brain Metastasis

Browse trials for

Keywords

  • Whole Brain Radiation Therapy
  • Stereotactic Radiosurgery
  • Brain metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older with 1-4 , each with a maximum diameter of no more than 3 cm on contrast-enhanced MRI scans, and were derived from a confirmed systemic cancer, Performance Status (KPS) score of 70 or more

Exclusion criteria

Exclusion Criteria:

  • Patients with from small cell carcinoma, lymphoma, germinoma, and multiple myeloma were excluded.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Defined population
Time perspective
Prospective
Enrollment
180 participants

Interventions

  • ProcedureWhole-Brain Radiation Therapy, Stereotactic Radiosurgery
06

Study locations

1 site
  • Hokkaido University School of Medicine
    Sapporo, Hokkaido 060-8638, Japan
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1999 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2006
First posted
Dec 4, 2006
Start
Oct 1999
Completion
Apr 2005
Last update
Dec 4, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Dec 4, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00406835
Lead sponsor
Hokkaido University Hospital
First posted
Dec 4, 2006
Start date
Oct 1999
Completion
Apr 2005
Last update
Dec 4, 2006

Study contacts

Hidefumi Aoyama, MD, PhD
principal investigator · Hokkaido University School of Medicine
Hiroki Shirato, MD, PhD
study chair · Hokkaido University School of Medicine
Keiichi Nakagawa, MD, PhD
study director · Tokyo University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion